Second-line treatment for advanced NSCLC without actionable mutations: is immunotherapy the ‘panacea’ for all patients?

The therapeutic approach for the second-line treatment of patients with advanced non-small cell lung cancer (NSCLC) without actionable mutations has been revolutionized by the recent approval of new effective ...

Source: BMC Medicine - February 16, 2018 Category: Internal Medicine Authors: Alessandro Morabito Tags: Commentary Source Type: research